在接受单克隆抗体治疗的患者中,B型肝炎病毒的重新激活
Silvia De Pauli1, Martina Grando1, Giovanni Miotti2
1Department of Internal Medicine, Azienda Sanitaria Friuli Occidentale, San Vito al Tagliamento, Pordenone 33170, Italy.
World journal of virology
|April 15, 2024
概括
乙型肝炎病毒 (HBV) 再激活是免疫抑制疗法 (如单克隆抗体) 期间的风险. 早期风险评估,监测和预防对于管理HBV再激活和确保患者安全至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 乙型肝炎病毒 (HBV) 的重新激活是免疫抑制患者的严重临床问题.
- 单克隆抗体疗法可以增加HBV重新激活的风险.
- 需要有效的管理策略来减轻这种风险.
研究的目的:
- 探索单克隆抗体治疗和HBV重新激活之间的关系.
- 审查HBV重新激活的定义,风险和管理.
- 改善临床决策和患者的治疗结果.
主要方法:
- 目前研究和临床案例研究的文献综述.
- 对HBV重新激活背后的机制的分析.
- 评估风险因素和管理协议.
主要成果:
- 单克隆抗体治疗与HBV重新激活的显著风险有关.
- 了解这些机制是有效预防和管理的关键.
- 预防措施和警监测至关重要.
结论:
- 有信息的临床决策对于管理单克隆抗体患者的HBV活性化至关重要.
- 早期查,预防和治疗改善了患者的治疗结果.
- 进一步的研究可以优化对HBV重新激活的管理策略.
更多相关视频
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
2.9K
12:09Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
Published on: February 28, 2019
9.8K
相关概念视频
Cross-reactivity
31.1K
Overview
31.1K
Hybridoma Technology
14.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K
B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K
